Through this investment, KÄÄPÄ Biotech will be better equipped to bring its range of functional mushroom extracts to businesses and consumers alike, writes Nutraceutical Business Review.
KÄÄPÄ Biotech announced it has closed a €900,000 strategic investment from PeakBridge, a pioneering global fund manager in agri-food and a member of the Edmond de Rothschild Private Equity partnership. The funding will be used to further enable KÄÄPÄ Biotech to scale its business to meet customer demand, and help bring functional mushroom ingredients to the forefront of global wellness.
"The functional mushroom market is currently experiencing rapid expansion, so we're seeing huge interest from companies either looking to enter the market of expand their presence," said KÄÄPÄ Biotech's CEO and co-founder, Eric Puro.
"Currently, we provide more than 180 companies across 20 markets with our functional mushroom ingredients. Through the investment from PeakBridge, we will drive a new phase of growth; continuing efforts to scale our business to match the increase in consumer demand," he added.
"Health and nutrition has always been a key investment focus for us, and in this space, functional mushrooms are emerging as a star ingredient," said PeakBridge's Seed Fund Managing Director (FoodSparks), Yoni Glickman.
"KÄÄPÄ Biotech stood out to us due to its unique extraction technology and clinically validated products. Their focus on growing their own mushrooms also ensures traceability, supply stability and consistent quality — all of which are critical elements in this fast-growing sector."
Read the article on Nutraceutical Business Review